Impact Biomedical says Zoar files SEC F-4 for proposed merger

PUBT · 2d ago
Impact Biomedical says Zoar files SEC F-4 for proposed merger
  • Zoar filed a Form F-4 on Sept. 10, 2026 for its planned merger with Impact Biomedical.
  • The filing includes Impact’s preliminary proxy materials, a key step toward closing the transaction.
  • Closing remains subject to SEC effectiveness, Impact stockholder vote, NYSE American listing clearance, other conditions.
  • The combined group is expected to focus on developing and supplying active pharmaceutical ingredients and intermediates for specialty therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160920PRIMZONEFULLFEED9828203) on September 16, 2026, and is solely responsible for the information contained therein.